Shortened polycystin-1 polypeptide and use thereof
Patent Information
- Application Number
- MYPI2025000489
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-04
- Filing Date
- 2023-08-03
- Publication Date
- 2024-02-04
AI Technical Summary
Autosomal dominant polycystic kidney disease (ADPKD) poses a challenge due to the large size of the PKD1 gene and difficulties in introducing genes for functional recovery of polycystin 1 (PC1), as well as uncertainty about the required region and location for functional recovery.
The use of truncated polycystin 1 polypeptides, specifically the C-terminal tail region, encoded by polynucleotides, which can inhibit cyst formation and be used in gene therapy to treat PKD1-related diseases by restoring PC1 function.
The truncated PC1 polypeptides effectively inhibit cyst formation, providing a potential treatment for ADPKD by restoring PC1 function, as demonstrated by evaluation results showing reduced total cyst area in cellular models.
Smart Images

Figure PI2025000489_DRAWING_001 
Figure PI2025000489_DRAWING_002 
Figure PI2025000489_DRAWING_003
Abstract
Description
Truncated polycystin 1 polypeptides and uses thereof
[0001] The present disclosure relates to truncated polycystin 1 polypeptides and uses thereof, particularly for the treatment of PKD1-related diseases.
[0002] Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, in which numerous cysts develop and grow progressively in both kidneys, causing damage to various organs other than the kidneys. ADPKD is a hereditary disease caused by the PKD1 and PKD2 genes, and 85% of patients are thought to have an abnormality in the PKD1 gene. The PKD1 gene encodes polycystin 1 (PC1), an 11-transmembrane protein, which cooperates with polycystin 2 (PC2), a 6-transmembrane protein encoded by the PKD2 gene, to transport Ca into cells. 2+ It is thought that loss of PC1 or PC2 function due to mutations in the PKD1 or PKD2 genes leads to cyst formation.
[0003] Gene therapy is an option for treating genetic diseases such as ADPKD, but the PKD1 gene is very large, approximately 13 kb, making gene transfer difficult. Furthermore, it is unclear which regions of PC1 are necessary for PC1 functional recovery and where they should be located within the cell. The present disclosure aims to provide a truncated form of PC1 that can be used to restore PC1 function and / or methods for using the same.
[0004] In one aspect, the present disclosure provides a polynucleotide comprising a sequence encoding a truncated polycystin 1 (PC1) having an inhibitory effect on cyst formation, wherein the truncated PC1 comprises the C-terminal tail (CTT) region of PC1 or a portion thereof.
[0005] In one aspect, the disclosure provides a polynucleotide comprising a sequence encoding a truncated polycystin 1 (PC1), wherein the truncated PC1 is a membrane-localized polypeptide comprising the C-terminal tail (CTT) region of PC1 or a portion thereof.
[0006] In one aspect, the disclosure provides a truncated PC1 polypeptide encoded by the polynucleotide.
[0007] In one aspect, the disclosure provides a vector comprising the polynucleotide.
[0008] In one aspect, the present disclosure provides a pharmaceutical composition for treating a PKD1-associated disease, comprising the polynucleotide or vector.
[0009] The present disclosure provides a truncated PC1 that can be used to restore PC1 function, enabling treatment of PKD1-related diseases, particularly gene therapy.
[0010] Figure 1 shows the structures of PC1, truncated PC1 polypeptide (CTF), and PC1 (Arg1672fs97X). Figure 2 shows the structures of various truncated PC1 polypeptides. Figure 3 shows the results of evaluating the cyst formation inhibitory effects of PC1, PC1 (Arg1672fs97X), and truncated polypeptides (CTF, CTT). pEB represents the control. The vertical axis shows the sum of cyst areas (μm 2 ) are shown. Figure 4 shows the results of evaluating the cyst formation inhibitory effect of various truncated PC1 polypeptides. pEB represents the control. The vertical axis represents the sum of cyst areas (μm 2 ) are shown. Figure 5 shows the structures of truncated PC1 polypeptides CD16.7-CTT and FAS-CTT. Figure 6 shows the results of evaluating the inhibitory effect of CD16.7-CTT and FAS-CTT on cyst formation. pEB represents the control. The vertical axis represents the sum of cyst areas (μm 2 ) are shown. Figure 7 shows partial regions of the CTT region contained in various truncated PC1 polypeptides. The numbers in the figure indicate the amino acid numbers in SEQ ID NO: 1. NLS: nuclear localization signal. Figure 8-1 shows the results of evaluation of the cyst formation inhibitory effect of various truncated PC1 polypeptides containing partial regions of the CTT region (1). pEB indicates the control, and the vertical axis shows the sum of cyst areas (μm 2) are shown (same for Figures 8-2 to 8-4). Figure 8-2 shows the results of an evaluation of the cyst formation inhibitory effect of various truncated PC1 polypeptides containing a partial region of the CTT region (2). Figure 8-3 shows the results of an evaluation of the cyst formation inhibitory effect of various truncated PC1 polypeptides containing a partial region of the CTT region (3). Figure 8-4 shows the results of an evaluation of the cyst formation inhibitory effect of various truncated PC1 polypeptides containing a partial region of the CTT region (4). Figure 9-1 shows the expression analysis of truncated PC1 polypeptides in MDCK cells by HPLC-MS (identification of peptides within the CTT region). The vertical axis (abundance) indicates the detection intensity of peptides by HPLC-MS (same for Figures 9-2 and 10-1 to 10-2). Figure 9-2 shows the expression analysis of truncated PC1 polypeptides in MDCK cells by HPLC-MS (identification of peptides within the CTF1 1-transmembrane domain). Figure 10-1 shows the analysis of plasma membrane localization of truncated PC1 polypeptide in MDCK cells by HPLC-MS (identification of peptides within the CTT domain). Figure 10-2 shows the analysis of plasma membrane localization of truncated PC1 polypeptide in MDCK cells by HPLC-MS (identification of peptides within the CTF11 transmembrane domain).
[0011] Unless otherwise specified, terms used herein have the meanings commonly understood by those skilled in the art of organic chemistry, medicine, pharmacology, molecular biology, microbiology, etc. Definitions of some terms used herein are provided below, but these definitions take precedence over common understandings in this specification.
[0012] The PKD1 gene encodes polycystin 1 (PC1), an 11-transmembrane protein with its N-terminus present extracellularly and its C-terminus present intracellularly. PC1 forms a complex with PC2, a 6-transmembrane protein with both its N- and C-termini present intracellularly, at the coiled-coil domain in the intracellular region, and transmits a signal to PC2, which functions as a calcium ion channel, allowing Ca ions to enter the cell. 2+ is allowed to flow in.
[0013] PC1 has a G protein-coupled receptor proteolytic site (GPS) as an enzymatic cleavage site and is composed of an extracellular N-terminal region N-terminal to the GPS and a C-terminal fragment (CTF) region C-terminal to the GPS. The CTF region comprises a stalk, 11 transmembrane domains, and a C-terminal tail (CTT) region. The stalk is the N-terminal extracellular region of the CTF region, i.e., the region from the N-terminus of the CTF region to the first transmembrane domain (TM1). In the present disclosure, PC1 can be PC1 from a mammal, such as a human or a non-human mammal. In one embodiment, PC1 is human PC1. A representative amino acid sequence of human PC1 is shown in SEQ ID NO: 1, and the nucleotide sequence encoding it is shown in SEQ ID NO: 2. Human PC1 and the nucleotide sequence encoding it are not limited to SEQ ID NOs: 1 and 2, respectively. For example, human PC1 may have an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 1 in that it contains natural mutations such as SNPs. Furthermore, the nucleotide sequence encoding human PC1 may have a sequence different from that of SEQ ID NO: 2 due to degeneracy of the genetic code. Those skilled in the art can identify each region of PC1 based on existing reports (Nat Genet, 1995 Jun;10(2):151-60; Biochemistry 2003, 42, 13035-13048; Science 361, 992 (2018); Dev Cell 22, 197-210, Jan 17, 2012), or by using amino acid domain / motif databases or transmembrane region prediction tools, such as Uniprot (https: / / www.uniprot.org / ), NCBI (https: / / www.ncbi.nlm.nih.gov / ), and predictprotein (https: / / predictprotein.org / ). In SEQ ID NO: 1, the extracellular N-terminal region, the stalk, the 11-transmembrane region, and the CTT region can be identified as amino acid sequences 1 to 3048, 3049 to 3074, 3075 to 4101, and 4102 to 4303, respectively.
[0014] A truncated PC1 is a polypeptide lacking a portion of the amino acid sequence of full-length PC1. In addition to the partial sequence of PC1, the truncated PC1 may contain a sequence not derived from PC1. The lengths of the partial sequences of PC1 in the truncated PC1 are 4300, 4200, 4100, 4000, 3900, 3800, 3700, 3600, 3500, 3400, 3300, 3200, 3100, 3000, 2900, 2800, 2700, 2600, 2500, 2400, 2300, 2200, 2400, 2500, 2600, 2700, 2800, 2900, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 39 ... 00, 2100, 2000, 1900, 1800, 1700, 1600, 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200 , 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, or 50 amino acids or less, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210 , 220, 230, 240, 250, 260, 270, 280, 290, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids or more. The length of the PC1 subsequence in the truncated PC1 may be 140 to 260, 150 to 250, 160 to 240, 170 to 230, 180 to 220, or 190 to 210 amino acids, such as 226, 202, or 190 amino acids. Alternatively, the length of the PC1 subsequence in the truncated PC1 may be 40 to 200, 50 to 150, or 50 to 100 amino acids. The PC1 subsequence in the truncated PC1 may be a single contiguous sequence in the full-length PC1, or may consist of multiple discontinuous subsequences. In one embodiment, the truncated PC1 lacks at least a portion of the extracellular N-terminal region of PC1. In one embodiment, the truncated PC1 lacks the entire extracellular N-terminal region of PC1. In one embodiment, the truncated PC1 lacks the entire extracellular N-terminal region and also lacks at least a portion of the stalk and 11-transmembrane region of PC1.In one embodiment, the truncated PC1 lacks the entire extracellular N-terminal region of PC1, the stalk, and all 11 transmembrane regions. The lengths of the truncated PC1 are: 4300, 4200, 4100, 4000, 3900, 3800, 3700, 3600, 3500, 3400, 3300, 3200, 3100, 3000, 2900, 2800, 2700, 2600, 2500, 2400, 2300, 2200, 2100, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 80 000, 1900, 1800, 1700, 1600, 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 1 It can be 80, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, or 50 amino acids or less, or 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids or more.
[0015] The truncated PC1 of the present disclosure comprises a CTT region or a portion thereof. As used herein, including "a CTT region or a portion thereof" is synonymous with including "at least a portion of the CTT region." The CTT region is an intracellular region of PC1. The length of the CTT region may be 230, 220, 210, 200, 190, 180, 170, 160, 150, or 140 amino acids or less, or 140, 150, 160, 170, 180, 190, or 200 amino acids or more. For example, the length of the CTT region may be 140 to 260, 150 to 250, 160 to 240, 170 to 230, 180 to 220, 190 to 210 amino acids, e.g., 226, 202, or 190 amino acids.
[0016] In SEQ ID NO: 1, the CTT region can be identified as the amino acid sequence from 4102 to 4303 (SEQ ID NO: 3). In SEQ ID NO: 2, the sequence encoding the CTT region can be identified as the nucleotide sequence from 12304 to 12909 (SEQ ID NO: 4).
[0017] In one embodiment, the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 3. In one embodiment, the CTT region comprises or consists of the sequence of SEQ ID NO: 3, or a sequence in which 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 3. In one embodiment, the CTT region comprises or consists of the sequence of positions 3 to 202 of SEQ ID NO: 3.
[0018] The sequence of the polynucleotide encoding the CTT region is not particularly limited, as long as it encodes the CTT region described herein. In one embodiment, the sequence encoding the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 3. In one embodiment, the sequence encoding the CTT region comprises or consists of a sequence encoding SEQ ID NO: 3, or a sequence in which 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of SEQ ID NO: 3. In one embodiment, the sequence encoding the CTT region comprises or consists of a sequence encoding the sequence of SEQ ID NO: 3. In one embodiment, the sequence encoding the CTT region comprises or consists of a sequence encoding the sequence from positions 3 to 202 of SEQ ID NO: 3.
[0019] In one embodiment, the sequence encoding the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:4. In one embodiment, the sequence encoding the CTT region comprises or consists of the sequence of SEQ ID NO: 4, or a sequence in which 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been modified in the sequence of SEQ ID NO: 4. In one embodiment, the sequence encoding the CTT region comprises or consists of the sequence of SEQ ID NO: 4. In one embodiment, the sequence encoding the CTT region comprises or consists of the sequence from bases 7 to 606 of SEQ ID NO: 4. The sequence encoding the CTT region may have a sequence different from SEQ ID NO: 4 or the sequence from bases 7 to 606 of SEQ ID NO: 4 due to degeneracy of the genetic code.
[0020] The portion of the CTT region can be any portion of the CTT region. The length of the portion of the CTT region can be 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, or 50 amino acids or less, or 40, 50, 60, 70, 80, 90, or 100 amino acids or more. For example, the length of the portion of the CTT region can be 40 to 200, 50 to 150, or 50 to 100 amino acids.
[0021] In one embodiment, the portion of the CTT region comprises or consists of at least a portion of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4154 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of at least a portion of the sequence of positions 4154 to 4303 of SEQ ID NO: 1, or a sequence in which 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of positions 4154 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of at least a portion of the sequence from positions 4154 to 4303 of SEQ ID NO:1.
[0022] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4204 to 4243 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4243 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4204 to 4243 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4243 of SEQ ID NO: 1.
[0023] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4104 to 4203 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4104 to 4203 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of positions 4104 to 4203 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4104 to 4203 of SEQ ID NO: 1.
[0024] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4154 to 4253 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4154 to 4253 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4154 to 4253 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4154 to 4253 of SEQ ID NO: 1.
[0025] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4154 to 4243 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4154 to 4243 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4154 to 4243 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4154 to 4243 of SEQ ID NO: 1.
[0026] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4193 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4193 to 4303 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4193 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4193 to 4303 of SEQ ID NO: 1.
[0027] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4204 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4303 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of positions 4204 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4303 of SEQ ID NO: 1.
[0028] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4204 to 4253 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4253 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4204 to 4253 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4204 to 4253 of SEQ ID NO: 1.
[0029] In one embodiment, the portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 4254 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4254 to 4303 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 4254 to 4303 of SEQ ID NO: 1. In one embodiment, the portion of the CTT region comprises or consists of the sequence of positions 4254 to 4303 of SEQ ID NO: 1.
[0030] The sequence of the polynucleotide encoding a portion of the CTT region is not particularly limited, as long as it encodes a portion of the CTT region described herein. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding at least a portion of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 4154 to 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding at least a portion of the sequence from position 4154 to position 4303 of SEQ ID NO: 1, or a sequence in which 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 4154 to 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding at least a portion of the sequence from position 4154 to 4303 of SEQ ID NO: 1.
[0031] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4204 to position 4243 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4243 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 4204 to position 4243 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4243 of SEQ ID NO: 1.
[0032] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4104 to position 4203 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4104 to position 4203 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 4104 to position 4203 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4104 to position 4203 of SEQ ID NO: 1.
[0033] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4154 to position 4253 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4154 to position 4253 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 4154 to position 4253 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4154 to position 4253 of SEQ ID NO: 1.
[0034] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4154 to position 4243 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4154 to position 4243 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 4154 to position 4243 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4154 to position 4243 of SEQ ID NO: 1.
[0035] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4193 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4193 to position 4303 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 4193 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4193 to position 4303 of SEQ ID NO: 1.
[0036] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4204 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4303 of SEQ ID NO: 1, or a sequence in which 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 4204 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4303 of SEQ ID NO: 1.
[0037] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4204 to position 4253 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4253 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 4204 to position 4253 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4204 to position 4253 of SEQ ID NO: 1.
[0038] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 4254 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4254 to position 4303 of SEQ ID NO: 1, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 4254 to position 4303 of SEQ ID NO: 1. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence encoding the sequence from position 4254 to position 4303 of SEQ ID NO: 1.
[0039] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of at least a portion of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 12460 to 12909 of SEQ ID NO:2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of at least a portion of the sequence from positions 12460 to 12909 of SEQ ID NO: 2, or a sequence in which 1 to 135, 1 to 130, 1 to 125, 1 to 120, 1 to 115, 1 to 110, 1 to 105, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from positions 12460 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of at least a portion of the sequence from bases 12460 to 12909 of SEQ ID NO: 2. The sequence encoding a portion of the CTT region may have a sequence that differs from at least a portion of the sequence from bases 12460 to 12909 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0040] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 12610 to 12729 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12729 of SEQ ID NO: 2, or a sequence in which 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been modified in the sequence from bases 12610 to 12729 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12729 of SEQ ID NO: 2. The sequence encoding a portion of the CTT region may have a sequence different from the sequence from bases 12610 to 12729 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0041] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity with the sequence from positions 12310 to 12609 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12310 to 12609 of SEQ ID NO: 2, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12310 to 12609 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12310 to 12609 of SEQ ID NO: 2. The sequence encoding a part of the CTT region may have a sequence different from the sequence from positions 12310 to 12609 of SEQ ID NO: 2 due to the degeneracy of the genetic code.
[0042] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 12460 to 12759 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12460 to 12759 of SEQ ID NO: 2, or the sequence from bases 12460 to 12729 of SEQ ID NO: 2, in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been modified. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12460 to 12759 of SEQ ID NO: 2. The sequence encoding a part of the CTT region may have a sequence different from the sequence from positions 12460 to 12759 of SEQ ID NO: 2 due to the degeneracy of the genetic code.
[0043] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity with the sequence from positions 12460 to 12729 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12460 to 12729 of SEQ ID NO: 2, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12460 to 12729 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12460 to 12729 of SEQ ID NO: 2. The sequence encoding a part of the CTT region may have a sequence different from the sequence from positions 12460 to 12729 of SEQ ID NO: 2 due to the degeneracy of the genetic code.
[0044] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 12577 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12577 to 12909 of SEQ ID NO: 2, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12577 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12577 to 12909 of SEQ ID NO: 2. The sequence encoding a part of the CTT region may have a sequence different from the sequence from positions 12577 to 12909 of SEQ ID NO: 2 due to the degeneracy of the genetic code.
[0045] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity with the sequence from positions 12610 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12909 of SEQ ID NO: 2, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12610 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12909 of SEQ ID NO: 2. The sequence encoding a part of the CTT region may have a sequence different from the sequence from positions 12610 to 12909 of SEQ ID NO: 2 due to the degeneracy of the genetic code.
[0046] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 12610 to 12759 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12759 of SEQ ID NO: 2, or a sequence in which 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12610 to 12759 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12610 to 12759 of SEQ ID NO: 2. The sequence encoding a portion of the CTT region may have a sequence different from the sequence from bases 12610 to 12759 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0047] In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 12760 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12760 to 12909 of SEQ ID NO: 2, or a sequence in which 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence from bases 12760 to 12909 of SEQ ID NO: 2. In one embodiment, the sequence encoding a portion of the CTT region comprises or consists of the sequence from bases 12760 to 12909 of SEQ ID NO: 2. The sequence encoding a portion of the CTT region may have a sequence different from the sequence from bases 12760 to 12909 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0048] In one embodiment, the truncated PC1 is a membrane-localized polypeptide. A membrane-localized polypeptide refers to a polypeptide that is localized in the cell membrane when expressed in a cell.
[0049] In one embodiment, the truncated PC1 further comprises, in addition to the CTT region or a portion thereof, at least a portion of the stalk of PC1. In one embodiment, the truncated PC1 further comprises, in addition to the CTT region, at least a portion of the stalk of PC1 and at least one transmembrane region. In one embodiment, the truncated PC1 further comprises, in addition to the CTT region, a signal sequence. In one embodiment, the truncated PC1 further comprises, in addition to the CTT region, a signal sequence and at least one transmembrane region.
[0050] In one embodiment, at least a portion of the stalk consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids, for example, 25 or 26 amino acids. In one embodiment, at least a portion of the stalk comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 3049 to 3074 of SEQ ID NO: 1. In one embodiment, at least a portion of the stalk comprises or consists of the sequence 3049-3074 of SEQ ID NO: 1, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids are altered in the sequence 3049-3074 of SEQ ID NO: 1. In one embodiment, at least a portion of the stalk comprises or consists of the sequence 3049-3074 of SEQ ID NO: 1.
[0051] The sequence of a polynucleotide encoding at least a portion of a stalk is not particularly limited, as long as it encodes at least a portion of a stalk as described herein. In one embodiment, the sequence encoding at least a portion of a stalk comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of bases 3049-3074 of SEQ ID NO: 1. In one embodiment, the sequence encoding at least a portion of a stalk comprises or consists of a sequence encoding bases 3049-3074 of SEQ ID NO: 1, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of bases 3049-3074 of SEQ ID NO: 1. In one embodiment, the sequence encoding at least a portion of a stalk comprises or consists of a sequence encoding bases 3049-3074 of SEQ ID NO: 1.
[0052] In one embodiment, the sequence encoding at least a portion of the stalk comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence at positions 9145-9222 of SEQ ID NO: 2. In one embodiment, the sequence encoding at least a portion of the stalk comprises or consists of the sequence at positions 9145-9222 of SEQ ID NO: 2, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are altered in the sequence at positions 9145-9222 of SEQ ID NO: 2. In one embodiment, the sequence encoding at least a portion of the stalk comprises or consists of the sequence at positions 9145-9222 of SEQ ID NO: 2. The sequence encoding at least a portion of the stalk may have a sequence that differs from the sequence from positions 9145 to 9222 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0053] A transmembrane region is a region of a polypeptide that penetrates a cell membrane, which is a lipid bilayer. In the truncated PC1 of the present disclosure, the transmembrane region may be derived from any protein, as long as it can anchor the truncated PC1 to the cell membrane. Examples of the transmembrane region include the transmembrane region of PC1, as well as the transmembrane regions of the α-chain and β-chain of the T cell receptor (TCR), CD3ε, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD95, CD134, CD137, CD154, PKD2, VSV-G (vesicular stomatitis virus G protein), and PLAP (placental alkaline phosphatase).
[0054] In one embodiment, the at least one transmembrane region comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 transmembrane regions.
[0055] PC1 has 11 transmembrane regions (designated TM1, TM2, TM3, TM4, TM5, TM6, TM7, TM8, TM9, TM10, and TM11 from the N-terminus). In one embodiment, at least one transmembrane region comprises at least one or a portion of the transmembrane regions of PC1. In one embodiment, at least one transmembrane region comprises TM1-TM11, TM2-TM11, TM3-TM11, TM4-TM11, TM5-TM11, TM6-TM11, TM7-TM11, TM8-TM11, TM9-TM11, TM10-TM11, or TM11 of PC1. In one embodiment, at least one transmembrane region comprises TM1-TM11 or TM6-TM11.
[0056] As used herein, when "at least one transmembrane region" includes two or more transmembrane regions, the amino acid sequence of the "at least one transmembrane region" also includes the amino acid sequence of the extracellular region and / or intracellular region between the transmembrane regions. In one embodiment, the at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 3075 to 4101 of SEQ ID NO: 1. In one embodiment, the at least one transmembrane region is selected from the group consisting of a sequence from 3075 to 4101 of SEQ ID NO: 1, or 1 to 300, 1 to 290, 1 to 280, 1 to 270, 1 to 260, 1 to 250, 1 to 240, 1 to 230, 1 to 220, 1 to 210, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 14 In one embodiment, at least one transmembrane region comprises or consists of a sequence from 3075 to 4101 of SEQ ID NO: 1.
[0057] In one embodiment, at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 3602 to 4101 of SEQ ID NO:1. In one embodiment, at least one transmembrane region comprises or consists of the sequence from bases 3602 to 4101 of SEQ ID NO: 1, or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids are modified. In one embodiment, at least one transmembrane domain comprises or consists of the sequence from positions 3602 to 4101 of SEQ ID NO:1.
[0058] In one embodiment, at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 244 to position 264 of SEQ ID NO: 21. In one embodiment, at least one transmembrane region comprises or consists of the sequence from position 244 to position 264 of SEQ ID NO: 21, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 244 to position 264 of SEQ ID NO: 21. In one embodiment, at least one transmembrane region comprises or consists of the sequence from position 244 to position 264 of SEQ ID NO: 21.
[0059] In one embodiment, at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 174 to 190 of SEQ ID NO: 24. In one embodiment, at least one transmembrane region comprises or consists of the sequence from bases 174 to 190 of SEQ ID NO: 24, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from bases 174 to 190 of SEQ ID NO: 24. In one embodiment, at least one transmembrane region comprises or consists of the sequence from bases 174 to 190 of SEQ ID NO: 24.
[0060] The sequence of the polynucleotide encoding the transmembrane region is not particularly limited, as long as it encodes a transmembrane region described herein. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from bases 3075 to 4101 of SEQ ID NO: 1. In one embodiment, the sequence encoding at least one transmembrane region is selected from the group consisting of a sequence from 3075 to 4101 of SEQ ID NO: 1, or a sequence from 1 to 300, 1 to 290, 1 to 280, 1 to 270, 1 to 260, 1 to 250, 1 to 240, 1 to 230, 1 to 220, 1 to 210, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 185, 1 to 190, 1 to 215, 1 to 220, 1 to 230, 1 to 245, 1 to 250, 1 to 260, 1 to 275, 1 to 280, 1 to 290, 1 to 300, 1 to 310, 1 to 320, 1 to 330, 1 to 340, 1 to 350, 1 to 360, 1 to 370, 1 to 380, 1 to 390, 1 to 400, 1 to 4101 of SEQ ID NO: 1, or a sequence from 3075 to 4101 of SEQ ID NO: 1, or a sequence from 3075 to 4101 of SEQ ID NO: 1, or In one embodiment, the sequence encoding at least one transmembrane domain comprises or consists of a sequence encoding a sequence in which 0, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered. In one embodiment, the sequence encoding at least one transmembrane domain comprises or consists of a sequence encoding a sequence from position 3075 to 4101 of SEQ ID NO: 1.
[0061] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from positions 3602 to 4101 of SEQ ID NO:1. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding a sequence from position 3602 to position 4101 of SEQ ID NO: 1, or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 3602 to 4101 of SEQ ID NO: 1. In one embodiment, the sequence encoding at least one transmembrane domain comprises or consists of a sequence encoding the sequence from positions 3602 to 4101 of SEQ ID NO:1.
[0062] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 244 to position 264 of SEQ ID NO: 21. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding the sequence from position 244 to position 264 of SEQ ID NO: 21, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence from position 244 to position 264 of SEQ ID NO: 21. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding the sequence from position 244 to position 264 of SEQ ID NO: 21.
[0063] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 174 to position 190 of SEQ ID NO: 24. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding the sequence from position 174 to position 190 of SEQ ID NO: 24, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence from position 174 to position 190 of SEQ ID NO: 24. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence encoding the sequence from position 174 to position 190 of SEQ ID NO: 24.
[0064] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 9223 to position 12303 of SEQ ID NO: 2. In one embodiment, the sequence encoding at least one transmembrane region comprises 1 to 900, 1 to 800, 1 to 700, 1 to 600, 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 1 The sequence encoding at least one transmembrane region may comprise or consist of a sequence in which 30, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from bases 9223 to 12303 of SEQ ID NO: 2. The sequence encoding at least one transmembrane region may have a sequence that differs from the sequence from bases 9223 to 12303 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0065] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 10804 to position 12303 of SEQ ID NO: 2. In one embodiment, the sequence encoding at least one transmembrane region comprises 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 200, 1 to 200, 1 to 200, 1 to 200, 1 to 200, 1 to 300, 1 to 400, 1 to 500, 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 200, 1 to 200, 1 to 200, 1 to 300, 1 to 400, 1 to 5 ... The sequence encoding at least one transmembrane region may comprise or consist of a sequence in which 110, 1-100, 1-95, 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from bases 10804 to 12303 of SEQ ID NO: 2. The sequence encoding at least one transmembrane region may have a sequence that differs from the sequence from bases 10804 to 12303 of SEQ ID NO: 2 due to degeneracy of the genetic code.
[0066] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 730 to position 792 of SEQ ID NO: 22. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from position 730 to position 792 of SEQ ID NO: 22, or a sequence in which 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are altered in the sequence from position 730 to position 792 of SEQ ID NO: 22. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from position 730 to position 792 of SEQ ID NO: 22. The sequence encoding at least one transmembrane domain may have a sequence different from the sequence of positions 730 to 792 of SEQ ID NO: 22 due to the degeneracy of the genetic code.
[0067] In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence from position 520 to position 570 of SEQ ID NO: 25. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from position 520 to position 570 of SEQ ID NO: 25, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are altered in the sequence from position 520 to position 570 of SEQ ID NO: 25. In one embodiment, the sequence encoding at least one transmembrane region comprises or consists of the sequence from position 520 to position 570 of SEQ ID NO: 25. The sequence encoding at least one transmembrane domain may have a sequence different from the sequence of bases 520 to 570 of SEQ ID NO:25 due to the degeneracy of the genetic code.
[0068] The signal sequence may be derived from any protein as long as it can localize a truncated PC1 containing the signal sequence to the cell membrane. Examples of signal sequences include sequences derived from PC1, Igκ chain, CD16, CD95, CD116, CD137, or PKD2. Known sequences known to localize proteins to the cell membrane, such as the CAAX motif, may also be used (The EMBO Journal, vol. 10, no. 13, pp. 4033-4039, 1991). In one embodiment, the signal sequence comprises at least a portion of the signal sequence of PC1, Igκ chain, CD16, CD95, CD116, CD137, or PKD2.
[0069] In one embodiment, the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 21 of SEQ ID NO: 19. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 21 of SEQ ID NO: 19, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 21 of SEQ ID NO: 19. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 21 of SEQ ID NO: 19.
[0070] In one embodiment, the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 16 of SEQ ID NO: 21. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 16 of SEQ ID NO: 21, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 16 of SEQ ID NO: 21. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 16 of SEQ ID NO: 21.
[0071] In one embodiment, the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 25 of SEQ ID NO: 24. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 25 of SEQ ID NO: 24, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 25 of SEQ ID NO: 24. In one embodiment, the signal sequence comprises or consists of the sequence of positions 1 to 25 of SEQ ID NO: 24.
[0072] The sequence of the polynucleotide encoding the signal sequence is not particularly limited, as long as it encodes a signal sequence described herein. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 21 of SEQ ID NO: 19. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 21 of SEQ ID NO: 19, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 21 of SEQ ID NO: 19. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 21 of SEQ ID NO: 19.
[0073] In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 16 of SEQ ID NO: 21. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 16 of SEQ ID NO: 21, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 16 of SEQ ID NO: 21. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 16 of SEQ ID NO: 21.
[0074] In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 25 of SEQ ID NO: 24. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 25 of SEQ ID NO: 24, or a sequence in which 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been modified in the sequence of positions 1 to 25 of SEQ ID NO: 24. In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence encoding the sequence of positions 1 to 25 of SEQ ID NO: 24.
[0075] In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 63 of SEQ ID NO: 20. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 63 of SEQ ID NO: 20, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence of positions 1 to 63 of SEQ ID NO: 20. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 63 of SEQ ID NO: 20. The sequence encoding the signal sequence may have a sequence different from the sequence of positions 1 to 63 of SEQ ID NO: 20 due to the degeneracy of the genetic code.
[0076] In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 48 of SEQ ID NO: 22. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 48 of SEQ ID NO: 22, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence of positions 1 to 48 of SEQ ID NO: 22. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 48 of SEQ ID NO: 22. The sequence encoding the signal sequence may have a sequence different from the sequence of positions 1 to 48 of SEQ ID NO: 22 due to degeneracy of the genetic code.
[0077] In one embodiment, the sequence encoding the signal sequence comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of positions 1 to 75 of SEQ ID NO: 25. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 75 of SEQ ID NO: 25, or a sequence in which 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides are modified in the sequence of positions 1 to 75 of SEQ ID NO: 25. In one embodiment, the sequence encoding the signal sequence comprises or consists of the sequence of positions 1 to 75 of SEQ ID NO: 25. The sequence encoding the signal sequence may have a sequence different from the sequence of positions 1 to 75 of SEQ ID NO: 25 due to degeneracy of the genetic code.
[0078] When a polypeptide of the present disclosure comprises two or more portions, such as a signal sequence, at least one transmembrane region, and a CTT region, each portion may be connected by a linker, such as a peptide linker containing an amino acid such as glycine, serine, arginine, alanine, or proline.
[0079] When a truncated PC1 comprises two or more portions (and optionally linkers), a polynucleotide encoding the truncated PC1 can be prepared by linking polynucleotides encoding each portion (and optionally linkers) in frame.
[0080] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 5. In one embodiment, the truncated PC1 comprises or consists of a sequence having 1-500, 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-99% or more of the sequence of SEQ ID NO: 5. In one embodiment, the truncated PC1 comprises or consists of a sequence in which 0, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 amino acids have been altered.
[0081] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 5. ... a sequence encoding a sequence having 1-500, 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-90, or 1000 of the sequence of SEQ ID NO: 5. In one embodiment, the truncated PC1 encoding sequence comprises or consists of a sequence encoding 0, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 amino acids altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of a sequence encoding the sequence of SEQ ID NO:5.
[0082] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 6. ... a sequence having 1 to 1200, 1 to 1100, 1 to 1000, 1 to 900, 1 to 800, 1 to 700, 1 to 600, 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 160, 1 to 180, 1 to 190, 1 to 200, 1 to 210, 1 to 220, 1 to 230, 1 to 240, 1 to 250, 1 to 260, 1 to 270, 1 to 280, 1 to 310, 1 to 320, 1 to 330, 1 to 340, 1 to 350, 1 to 360, 1 to 370, 1 to 380, The truncated PC1 coding sequence may comprise or consist of a sequence in which up to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 coding sequence comprises or consists of the sequence of SEQ ID NO: 6. The truncated PC1 coding sequence may have a sequence different from that of SEQ ID NO: 6 due to the degeneracy of the genetic code.
[0083] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 19. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 19 or the sequence of SEQ ID NO: 19 in which 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 amino acids have been altered. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO:19.
[0084] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 19. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 19, or a sequence encoding SEQ ID NO: 19 in which 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding the sequence of SEQ ID NO:19.
[0085] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 20. ... a sequence having 1-700, 1-600, 1-500, 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, or more of the sequence of SEQ ID NO: 20. nucleotides, 1-95, 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 20. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 20 due to the degeneracy of the genetic code.
[0086] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:21. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 21 or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 21. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 21.
[0087] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:21. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 21, or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 21. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 21.
[0088] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 22. ... a sequence having 1-700, 1-600, 1-500, 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, or more of the sequence of SEQ ID NO: 22. nucleotides, 1-95, 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 22. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 22 due to the degeneracy of the genetic code.
[0089] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:24. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 24, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 24. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 24.
[0090] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:24. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 24, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 24. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 24.
[0091] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 25. ... a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, The truncated PC1 coding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 coding sequence comprises or consists of the sequence of SEQ ID NO: 25. The truncated PC1 coding sequence may have a sequence that differs from the sequence of SEQ ID NO: 25 due to the degeneracy of the genetic code.
[0092] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 36. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 36, or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 36. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 36.
[0093] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:36. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 36, or a sequence in which 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 36. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 36.
[0094] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 37. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, or more of the sequence of SEQ ID NO: 37. , 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 37. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 37 due to the degeneracy of the genetic code.
[0095] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 38. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 38, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 38. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 38.
[0096] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 38. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 38, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 38. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 38.
[0097] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 39. ... a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, The truncated PC1 encoding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of the sequence of SEQ ID NO: 39. The truncated PC1 encoding sequence may have a sequence that differs from the sequence of SEQ ID NO: 39 due to the degeneracy of the genetic code.
[0098] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:40. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 40, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 40. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 40.
[0099] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:40. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 40, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 40. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding the sequence of SEQ ID NO: 40.
[0100] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 41. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1100, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2 The truncated PC1 encoding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of the sequence of SEQ ID NO: 41. The truncated PC1 encoding sequence may have a sequence that differs from the sequence of SEQ ID NO: 41 due to the degeneracy of the genetic code.
[0101] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:42. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 42, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 42. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 42.
[0102] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:42. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 42, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 42. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 42.
[0103] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 43. ... a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, The truncated PC1 encoding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of the sequence of SEQ ID NO: 43. The truncated PC1 encoding sequence may have a sequence that differs from the sequence of SEQ ID NO: 43 due to the degeneracy of the genetic code.
[0104] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:44. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 44, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 44. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 44.
[0105] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:44. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 44, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 44. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 44.
[0106] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 45. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2 The truncated PC1 encoding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of the sequence of SEQ ID NO: 45. The truncated PC1 encoding sequence may have a sequence that differs from the sequence of SEQ ID NO: 45 due to the degeneracy of the genetic code.
[0107] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:46. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 46, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 46. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 46.
[0108] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:46. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 46, or a sequence in which 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 46. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 46.
[0109] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 47. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 1-400, 1-300, 1-200, 1-190, 1-180, 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 1-100, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-800, 1-900, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2000, 1-3000, 1-4000, 1-5000, 1-6000, 1-7000, 1-8000, 1-9000, 1-1000, 1-1200, 1-1300, 1-1400, 1-1500, 1-1600, 1-1700, 1-1800, 1-1900, 1-2000, 1-2000, 1-2 The truncated PC1 encoding sequence may comprise or consist of a sequence in which 90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, or 1, 2, or 3 nucleotides have been altered. In one embodiment, the truncated PC1 encoding sequence comprises or consists of the sequence of SEQ ID NO: 47. The truncated PC1 encoding sequence may have a sequence that differs from the sequence of SEQ ID NO: 47 due to the degeneracy of the genetic code.
[0110] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:48. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 48, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 48. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 48.
[0111] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:48. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 48, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 48. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 48.
[0112] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:49. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of SEQ ID NO:49 or a sequence in which 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been altered in SEQ ID NO:49. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 49. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 49 due to the degeneracy of the genetic code.
[0113] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:50. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 50, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 50. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 50.
[0114] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:50. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 50, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 50. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding the sequence of SEQ ID NO: 50.
[0115] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:51. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of SEQ ID NO:51 or a sequence in which 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been modified in SEQ ID NO:51. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 51. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 51 due to the degeneracy of the genetic code.
[0116] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 52. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 52, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 52. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 52.
[0117] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:52. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 52, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 52. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 52.
[0118] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:53. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of SEQ ID NO:53, or a sequence in which 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been altered in the sequence of SEQ ID NO:53. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 53. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 53 due to the degeneracy of the genetic code.
[0119] In one embodiment, the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO: 54. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 54, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 54. In one embodiment, the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 54.
[0120] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:54. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 54, or a sequence in which 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 amino acids have been altered in the sequence of SEQ ID NO: 54. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence encoding SEQ ID NO: 54.
[0121] In one embodiment, the sequence encoding the truncated PC1 comprises or consists of a sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity to the sequence of SEQ ID NO:55. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of SEQ ID NO:55, or a sequence in which 1 to 300, 1 to 200, 1 to 190, 1 to 180, 1 to 170, 1 to 160, 1 to 150, 1 to 140, 1 to 130, 1 to 120, 1 to 110, 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 4, or 1, 2, or 3 nucleotides have been altered in SEQ ID NO:55. In one embodiment, the sequence encoding the truncated PC1 comprises or consists of the sequence of SEQ ID NO: 55. The sequence encoding the truncated PC1 may have a sequence that differs from the sequence of SEQ ID NO: 55 due to the degeneracy of the genetic code.
[0122] As used herein, "at least a portion of a region or sequence" may refer to any part of that region or sequence, or may refer to the entire region or sequence.
[0123] As used herein, a sequence "comprising" a given sequence is used to mean a sequence in which one or more amino acids (in the case of an amino acid sequence) or nucleotides (in the case of a nucleotide sequence) are added to the given sequence, and a sequence consisting of the given sequence.
[0124] With respect to amino acid sequences or nucleotide sequences, sequence identity refers to the percentage of amino acid residues or bases that match between two sequences aligned optimally (maximum match). Sequence identity is calculated using the following formula: sequence identity (%) = [(matching amino acid residues or bases between two sequences) / (alignment length)] × 100. Sequence identity can be calculated using programs such as FASTA and BLAST.
[0125] Amino acid and nucleotide modifications include deletions, substitutions, insertions, and additions of amino acids and nucleotides, and the modifications may be any one of deletions, substitutions, insertions, and additions, or a combination of two or more of these.
[0126] Those skilled in the art can confirm the inhibitory effect on cyst formation using appropriate methods. For example, a cyst formation model such as that described in the Examples or in a literature article (Yan B. et al., J Am Soc Nephrol 19: 1300-1310, 2008) can be used. When Madin-Darby canine kidney (MDCK) cells derived from canine kidney tubular epithelial cells are three-dimensionally cultured on collagen gel and stimulated with forskolin, cyst formation is observed. Addition of EGF in addition to forskolin can shorten the time to cyst formation (Molecular Cell 6: 1267-1273, 2000). When MDCK cells expressing truncated PC1 by introducing a polynucleotide encoding truncated PC1 or a vector containing the same exhibit suppressed cyst formation compared to controls, the truncated PC1 can be determined to have an inhibitory effect on cyst formation. The truncated PC1 of the present disclosure may, for example, inhibit cyst formation by at least 20%, 30%, 40%, 50%, 60%, 70%, or 80% compared to a control.
[0127] By administering a polynucleotide containing a sequence encoding a truncated PC1 or a vector containing the same to a subject, the truncated PC1 can be expressed in the subject. The polynucleotide may be DNA or RNA, and may contain one or more unnatural nucleotides.
[0128] A vector refers to a vector that can deliver a polynucleotide of a desired sequence into cells.The vector can be a viral vector or a non-viral vector.Viral vectors include retrovirus, lentivirus, adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), vaccinia virus, Sendai virus, or measles virus vector.Non-viral vectors include plasmid vectors, liposome vectors, and artificial chromosomes (e.g., YAC, BAC, PAC).Each vector can be prepared according to conventional methods.
[0129] The vector may contain one or more regulatory sequences that regulate the expression of the truncated PC1 coding sequence. Regulatory sequences include promoters, enhancers, polyadenylation signals, post-transcriptional regulatory elements (PREs), and other expression control elements. The promoter may be a constitutive promoter, an inducible promoter, or a tissue- or cell-specific promoter. Examples of promoters include the CMV (cytomegalovirus) promoter, the PGK (phosphoglycerate kinase) promoter, the EF1α (elongation factor 1-alpha) promoter, the CAG promoter, the SV40 promoter, and the MSCV promoter. Examples of polyadenylation signals include the SV40 polyadenylation signal, the bovine growth hormone gene polyadenylation signal, and the globulin polyadenylation signal. Examples of PRE include WPRE, Adenovirus tripartite leader sequence, Cytomegalovirus Intron A, and HSP70 5'UTR (untranslated region).
[0130] The vector may contain an origin of replication (ori) for its replication. It may also contain a marker for selecting cells containing the vector. Examples of the selection marker include genes that confer resistance to drugs such as neomycin, kanamycin, puromycin, hygromycin, zeocin, and ampicillin.
[0131] In one embodiment, the vector is an AAV vector. There are many serotypes of AAV, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-rhlO, AAV-DJ, and AAVAnc80. AAV vectors may be in their natural form or in their recombinant form, in which capsid proteins or the like have been modified. AAV vectors can be prepared, for example, by introducing an AAV vector plasmid containing a truncated PC1-encoding sequence (or a truncated PC1-encoding sequence placed downstream of a promoter) and its flanking ITRs (inverted terminal repeats) into packaging cells together with an AAV helper plasmid containing the Rep and Cap genes required for AAV replication and particle formation, and an adenovirus helper plasmid containing adenovirus helper genes required for AAV propagation. Examples of packaging cells include 293T cells, 293 cells, HeLa cells, COS1 cells, and COS7 cells. Viral particles released from packaging cells can be recovered from the packaging cell culture supernatant by purification methods such as centrifugation, filtration, and column purification.
[0132] In one embodiment, the vector is a lentiviral vector. Examples of lentiviral vectors include human immunodeficiency viruses (HIV) (e.g., HIV-1 and HIV-2), simian immunodeficiency viruses (SIV), feline immunodeficiency viruses (FIV), Maedi-Visna viruses (MVV), Maedi-Visna-like viruses (EV1), equine infectious anemia viruses (EIAV), and caprine arthritis encephalitis viruses (CAEV). Lentiviral vectors can be prepared, for example, by introducing a viral vector plasmid containing a truncated PC1 coding sequence (or a truncated PC1 coding sequence placed downstream of a promoter) and its flanking long terminal repeats (LTRs) (5'LTR and 3'LTR) and packaging signals into packaging cells together with one or more plasmid vectors expressing viral structural proteins such as Gag, Pol, and Env, or by introducing the viral vector plasmid into packaging cells expressing these structural proteins. The viral vector may be pseudotyped, and one or more plasmid vectors expressing an envelope protein such as vesicular stomatitis virus G protein (VSV-G) may be further introduced into the packaging cells. Examples of packaging cells include 293T cells, 293 cells, HeLa cells, COS1 cells, and COS7 cells. The viral particles released from the packaging cells can be recovered from the packaging cell culture supernatant by a purification method such as centrifugation, filtration, or column purification.
[0133] In one embodiment, the polynucleotide comprising a sequence encoding a truncated PC1 is RNA. In this embodiment, the polynucleotide may comprise a 5' cap structure, a 5' untranslated region (UTR), a truncated PC1 coding sequence, a 3' UTR, and a polyA sequence. Such a polynucleotide may be produced, for example, by in vitro transcription using plasmid DNA as a template. For intracellular delivery, the polynucleotide may be administered encapsulated in lipid particles or polymer particles.
[0134] By expressing the truncated PC1 of the present disclosure in a subject or by administering the truncated PC1 of the present disclosure to a subject, a PKD1-related disease can be treated. PKD1-related disease refers to a disease caused by loss of PC1 function due to a mutation in the PKD1 gene. PKD1-related diseases include cystic disease, hypertension, intracranial aneurysm, colonic diverticulum, heart valve regurgitation, and kidney stones. In one embodiment, the PKD1-related disease is a cystic disease. Cystic diseases include polycystic kidney disease (PKD), polycystic liver disease (PLD), nephronophthisis (NPHP), Bardet-Biedl syndrome (BBS), Meckel syndrome (MKS), Joubert syndrome (JBTS), oral facial digital syndrome (OFD), or pancreatic cysts. In one embodiment, the cystic disease is PKD. PKD includes autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).
[0135] In one embodiment, the PKD is ADPKD. ADPKD is a genetic disease caused by PKD1 and PKD2 genes, and 85% of patients are thought to have an abnormality in the PKD1 gene. PC1 and PC2 act to block Ca transport into cells. 2+It is believed that loss of function of PC1 or PC2 due to mutations in the PKD1 or PKD2 genes leads to cyst formation.
[0136] Treatment of a PKD1-associated disease includes amelioration or suppression of one or more symptoms or signs of the disease. For example, treatment of ADPKD includes suppression of kidney volume increase and kidney function decline due to ADPKD.
[0137] The polynucleotide, polypeptide, or vector is administered to a subject in an amount (referred to herein as an effective amount) that can exert a desired effect (e.g., therapeutic effect on a PKD1-related disease). The dosage is appropriately selected depending on the age, weight, health condition, etc. of the subject. In the case of an AAV vector, for example, about 10 9 ~10 15 vg (vector genome), 10 10 ~10 14 vg, or 10 10 ~10 13 In the case of a lentiviral vector, for example, about 10 vg per kg of body weight can be administered. 4 ~10 10 The vector may be administered in transducing units (TU). In the case of non-viral vectors, the vector may be administered at about 0.01 to 100 mg / kg of body weight. Administration may be daily, once every day or several days, once every week or several weeks, once every month or several months, or once every several years or a lifetime. The daily dose may be administered in a single dose or in multiple doses (e.g., 2 to 4 times).
[0138] The administration method is appropriately selected depending on the age, body weight, health condition, etc. of the subject. The administration method may be oral or parenteral, with parenteral administration being preferred. Examples of parenteral administration include subcutaneous administration, intradermal administration, intramuscular administration, intraperitoneal administration, intravenous administration, femoral artery-renal artery catheter administration, and ureteral retrograde administration.
[0139] In addition to the polynucleotide, polypeptide, or vector, the pharmaceutical composition may contain pharmaceutically acceptable carriers or additives such as sterile water, physiological saline, stabilizers, excipients, antioxidants, buffers, preservatives, surfactants, chelating agents, and binders. The dosage form may be, but is not limited to, an injection. Injections include solution injections, suspension injections, emulsion injections, and injections prepared immediately before use (e.g., lyophilized injections). The pharmaceutical composition may be provided as a kit, which may further include buffer solutions and instructions for use for preparation immediately before use.
[0140] The subject can be a mammal, such as a human or a non-human mammal. Non-human mammals include, for example, mice, rats, rabbits, cats, dogs, sheep, pigs, horses, cows, and monkeys. In one embodiment, the subject is a human.
[0141] Exemplary embodiments of the present disclosure are described below. [1] A polynucleotide comprising a sequence encoding truncated polycystin 1 (PC1) having an inhibitory effect on cyst formation, wherein the truncated PC1 comprises the C-terminal tail (CTT) region of PC1 or a portion thereof. [2] The polynucleotide described in 1 above, wherein the truncated PC1 comprises the CTT region of PC1. [3] The polynucleotide described in 1 above, wherein the truncated PC1 comprises a portion of the CTT region of PC1. [4] The polynucleotide described in any one of 1 to 3 above, wherein the truncated PC1 lacks at least a portion of the extracellular N-terminal region of PC1. [5] The polynucleotide described in any one of 1 to 4 above, wherein the truncated PC1 lacks the entire extracellular N-terminal region of PC1. [6] The polynucleotide described in any one of 1 to 5 above, wherein the truncated PC1 is a membrane-localized polypeptide. [7] A polynucleotide comprising a sequence encoding truncated polycystin 1 (PC1), wherein the truncated PC1 is a membrane-localized polypeptide comprising the C-terminal tail (CTT) region of PC1 or a portion thereof. [8] The polynucleotide according to claim 7, wherein the truncated PC1 comprises the CTT region of PC1. [9] The polynucleotide according to claim 7, wherein the truncated PC1 comprises a portion of the CTT region of PC1.
[10] The polynucleotide according to any one of claims 1 to 9, wherein the truncated PC1 further comprises at least a portion of the stalk of PC1.
[11] The polynucleotide according to claim 10, wherein the truncated PC1 further comprises at least one transmembrane region.
[12] The polynucleotide according to any one of claims 1 to 9, wherein the truncated PC1 further comprises a signal sequence.
[13] The polynucleotide according to claim 12, wherein the truncated PC1 further comprises at least one transmembrane region.
[14] The polynucleotide according to any one of 1 to 13, wherein the CTT region consists of a sequence having 90% or more sequence identity with the sequence of SEQ ID NO: 3.
[15] The polynucleotide according to any one of 1 to 14, wherein the CTT region consists of the sequence of SEQ ID NO: 3.
[16] The polynucleotide according to any one of 1 to 14, wherein the CTT region consists of the sequence from base 3 to base 202 of SEQ ID NO: 3.
[17] The polynucleotide according to any one of [1] to
[16] , wherein a portion of the CTT region comprises at least a portion of a sequence having 90% or more sequence identity with the sequence from bases 4154 to 4303 of SEQ ID NO: 1.
[18] The polynucleotide according to any one of [1] to
[17] , wherein a portion of the CTT region comprises at least a portion of a sequence having 90% or more sequence identity with the sequence from bases 4154 to 4303 of SEQ ID NO: 1.
[19] The polynucleotide according to any one of [1] to
[18] , wherein a portion of the CTT region comprises at least a portion of a sequence having 90% or more sequence identity with the sequence from bases 4204 to 4243 of SEQ ID NO: 1.
[20] The polynucleotide according to any one of [1] to
[19] , wherein a portion of the CTT region comprises a sequence having 90% or more sequence identity with the sequence from bases 4204 to 4243 of SEQ ID NO: 1.
[21] The polynucleotide according to any one of [1] to
[20] , wherein a portion of the CTT region comprises a sequence having 90% or more sequence identity with the sequence from bases 4204 to 4253 of SEQ ID NO: 1.
[22] The polynucleotide according to any one of [1] to
[21] above, wherein a portion of the CTT region comprises the sequence from bases 4204 to 4253 of SEQ ID NO: 1.
[23] The polynucleotide according to any one of [1] to 22] above, wherein the portion of the CTT region is 150 amino acids or less in length.
[24] The polynucleotide according to any one of
[11] and
[13] to 23] above, wherein at least one transmembrane region is selected from the transmembrane region or a portion thereof of PC1, the α chain or β chain of a T cell receptor, CD3ε, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD95, CD134, CD137, CD154, PKD2, VSV-G, or PLAP.
[25] The polynucleotide according to any one of 11 and 13 to 24 above, wherein at least one transmembrane region consists of a sequence having 90% or more sequence identity with the sequence from bases 3075 to 4101 of SEQ ID NO: 1.
[26] The polynucleotide according to 25 above, wherein at least one transmembrane region consists of a sequence from bases 3075 to 4101 of SEQ ID NO: 1.
[27] The polynucleotide according to any one of 11 and 13 to 24 above, wherein at least one transmembrane region consists of a sequence having 90% or more sequence identity with the sequence from bases 3602 to 4101 of SEQ ID NO: 1.
[28] The polynucleotide according to claim 27, wherein at least one transmembrane region consists of the sequence from bases 3602 to 4101 of SEQ ID NO: 1.
[29] The polynucleotide according to any one of claims 11 and 13 to 24, wherein at least one transmembrane region consists of a sequence having 90% or more sequence identity with the sequence from bases 244 to 264 of SEQ ID NO: 22.
[30] The polynucleotide according to claim 29, wherein at least one transmembrane region consists of the sequence from bases 244 to 264 of SEQ ID NO: 22.
[31] The polynucleotide according to any one of claims 11 and 13 to 24, wherein at least one transmembrane region consists of a sequence having 90% or more sequence identity with the sequence from bases 174 to 190 of SEQ ID NO: 24.
[32] The polynucleotide according to claim 31, wherein at least one transmembrane region consists of the sequence from bases 174 to 190 of SEQ ID NO: 24.
[33] The polynucleotide according to any one of 12 to 32, wherein the signal sequence comprises at least a portion of the signal sequence of PC1, Igκ chain, CD16, CD95, CD116, CD137, or PKD2.
[34] The polynucleotide according to any one of 12 to 33, wherein the signal sequence consists of a sequence having 90% or more sequence identity with the sequence of positions 1 to 21 of SEQ ID NO: 19.
[35] The polynucleotide according to 34, wherein the signal sequence consists of the sequence of positions 1 to 21 of SEQ ID NO: 19.
[36] The polynucleotide according to any one of 12 to 33, wherein the signal sequence consists of a sequence having 90% or more sequence identity with the sequence of positions 1 to 16 of SEQ ID NO: 21.
[37] The polynucleotide according to 36, wherein the signal sequence consists of the sequence of positions 1 to 16 of SEQ ID NO: 21.
[38] The polynucleotide according to any one of 12 to 33, wherein the signal sequence consists of a sequence having 90% or more sequence identity with the sequence of positions 1 to 25 of SEQ ID NO: 24.
[39] The polynucleotide according to 38, wherein the signal sequence consists of the sequence from bases 1 to 25 of SEQ ID NO: 24.
[40] The polynucleotide according to any one of 1 to 39, wherein the truncated PC1 comprises a sequence having 90% or more sequence identity with the sequence of SEQ ID NO: 5, 19, or 21.
[41] The polynucleotide according to claim 40, wherein the truncated PC1 comprises the sequence of SEQ ID NO: 5, 19, or 21.
[42] The polynucleotide according to any one of claims 1 to 41, wherein the truncated PC1 comprises a sequence having 90% or more sequence identity with the sequence of SEQ ID NO: 6, 20, or 22.
[43] The polynucleotide according to claim 42, wherein the truncated PC1 comprises the sequence of SEQ ID NO: 6, 20, or 22.
[44] The polynucleotide according to any one of claims 1 to 39, wherein the truncated PC1 comprises a sequence having 90% or more sequence identity with the sequence of SEQ ID NO: 24, 36, 38, 40, 42, 44, 46, 48, 50, 52, or 54.
[45] The polynucleotide according to claim 44, wherein the truncated PC1 comprises the sequence of SEQ ID NO: 24, 36, 38, 40, 42, 44, 46, 48, 50, 52, or 54.
[46] The polynucleotide according to any one of 1 to 39, 44, and 45, comprising a sequence having 90% or more sequence identity with the sequence of SEQ ID NO: 25, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55.
[47] The polynucleotide according to 46, comprising the sequence of SEQ ID NO: 25, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55.
[0142]
[48] A truncated polycystin 1 (PC1) polypeptide encoded by the polynucleotide according to any one of 1 to 47.
[0143]
[49] A vector comprising the polynucleotide according to any one of 1 to 47.
[50] The vector according to 49, wherein the vector is a viral vector or a non-viral vector.
[51] The vector according to 50, wherein the viral vector is a retrovirus, lentivirus, adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), vaccinia virus, Sendai virus, or measles virus vector.
[52] The vector according to 50, wherein the non-viral vector is a plasmid vector, liposome vector, or artificial chromosome.
[0144]
[53] A pharmaceutical composition for treating a PKD1-associated disease, comprising the polynucleotide described in any one of [1] to
[47] , the polypeptide described in
[48] , or the vector described in any one of
[49] to
[52] .
[54] The pharmaceutical composition described in
[53] , wherein the PKD1-associated disease is a cystic disease.
[55] The pharmaceutical composition described in
[54] , wherein the cystic disease is polycystic kidney disease (PKD), polycystic liver disease (PLD), nephronophthisis (NPHP), Bardet-Biedl syndrome (BBS), Meckel syndrome (MKS), Joubert syndrome (JBTS), orofacial-digital syndrome (OFD), or pancreatic cyst.
[56] The pharmaceutical composition described in
[55] , wherein the PKD is autosomal dominant polycystic kidney disease (ADPKD) or autosomal recessive polycystic kidney disease (ARPKD).
[57] The pharmaceutical composition according to 56, wherein the PKD is ADPKD.
[0145]
[58] The polynucleotide according to any one of 1 to 47, the polypeptide according to 48, or the vector according to any one of 49 to 52, for use in treating a PKD1-related disease.
[0146]
[59] A method for treating a PKD1-associated disease, comprising administering to a subject in need thereof an effective amount of the polynucleotide described in any one of 1 to 47, the polypeptide described in 48, or the vector described in any one of 49 to 52.
[0147]
[60] Use of the polynucleotide described in any one of 1 to 47, the polypeptide described in 48, or the vector described in any one of 49 to 52, for the manufacture of a medicament for treating a PKD1-associated disease.
[0148]
[61] A pharmaceutical composition for suppressing cyst formation in the kidney, comprising a polynucleotide comprising a sequence encoding a truncated polycystin-1 (PC1) designed to localize the C-terminal tail (CTT) region of PC1 or a portion thereof to the cell membrane, or a vector comprising the polynucleotide.
[0149]
[62] A pharmaceutical composition for suppressing cyst formation in the kidney, comprising a polynucleotide comprising a sequence encoding a truncated polycystin-1 (PC1) containing the C-terminal tail (CTT) region or a portion thereof, or a vector comprising the polynucleotide, and suppressing cyst formation by localizing the CTT region or a portion thereof to the cell membrane.
[0150]
[63] A pharmaceutical composition for suppressing cyst formation in the kidney, comprising a truncated polycystin-1 (PC1) designed to localize the C-terminal tail (CTT) region or a portion thereof to the cell membrane.
[0151]
[64] A pharmaceutical composition for suppressing cyst formation in the kidney, comprising a truncated polycystin-1 (PC1) containing the C-terminal tail (CTT) region of PC1 or a portion thereof, and suppressing cyst formation by localizing the CTT region or a portion thereof to the cell membrane.
[0152] The present invention will be further explained below with reference to examples, but the present invention is not limited to these examples in any sense.
[0153] Example 1 1. Test Method 1.1 Cells Madin-Darby canine kidney (MDCK) cells derived from canine kidney tubular epithelial cells were used.
[0154] 1.2 Construction of Expression Vector Polycystin 1 (PC1), a human PKD1 gene product shown in Table 1, and its partial regions were cloned from a PKD1 expression plasmid (Origene Technologies) and inserted into the multicloning site of the episomal vector pEBMulti-Hygb vector (Fujifilm Wako Pure Chemical Industries, Ltd.). To promote cell membrane translocation, an Igκ chain leader sequence (pDisplay TMVector (Invitrogen)) or CD16.7 (a fusion protein containing the extracellular domain of human CD16 and the transmembrane domain of human CD7 (Tsiokas 94:6965-6970 1997 PNAS) was added. PC1 (Arg1672fs97X) is a mutation found in patients with autosomal dominant polycystic kidney disease. R-CTF, in which the CTF coding sequence was inserted in the reverse orientation into a vector, was tested as a negative control that does not express CTF.
[0155] 1.3 Cellular introduction of expression vector and selection of transfected cells The prepared plasmid vector was purified from E. coli and transfected into MDCK cells using a Neon Transfection System (ThermoFisher Scientific). 7 A suspension of 1 μg of expression vector in 10 μL of cell suspension at 100 cells / mL was placed in a Neon Transfection System, and transformation by electroporation was performed under the conditions of voltage: 1150 V, width: 20 ms, number: 1. The resulting solution was added to the medium (DMEM / F12 containing 10% FCS) (1 mL / well, 12-well plate). The next day, the medium was replaced with the above medium supplemented with 500 μg / mL hygromycin (Life Technologies Japan), and the culture was continued for 6 to 8 days to select cells into which the expression vector had been introduced.
[0156] 1.4 Preparation and culture of collagen gel solution 3mg / mL PureCol (Advanced Cell Matrix Co) 74.09mL (2.25mg / mL), 10x MEM 10mL, inactivated fetal bovine serum (FBS) 10mL (10%), 1M HEPES 2 mL (20 mM), 0.75% NaHCO 3 2.91 mL (26 mM) of the collagen gel solution was mixed with 1 mL of sterile water and adjusted to pH 7.4 with 1 N NaOH to prepare a collagen gel solution (100 mL). 250 μL of the collagen gel solution was dispensed into each well of a 24-well plate (Corning 353047) and incubated at 37° C. in CO 2The next day, MDCK cells were mixed with 500 μL of collagen gel solution at 5,000 cells / well and layered. 2 After solidification was confirmed, forskolin (Fujifilm Wako Pure Chemical Industries, Ltd.) and EGF (Fujifilm Wako Pure Chemical Industries, Ltd.) were added to 750 μL of 10% FBS-containing DMEM / F12 medium to a final concentration of 20 mM and 20 μg / mL, respectively (in the test shown in FIG. 3, hygromycin was added to the same medium to a final concentration of 400 μg / mL), and the mixture was incubated at 37°C and CO 2 Culture was initiated in an incubator and continued for 8 to 12 days with medium changes (containing forskolin and EGF, and further containing hygromycin in the test shown in Figure 3) every 3 to 4 days.
[0157] 1.5 Automated Measurement of Cyst Size and Number Using a Cell Voyager CV6000 or CV8000 Bright-field images (equivalent to 32 4x objective lens areas per well) of 24-well plates containing cysts were taken using a Cell Voyager CV6000 or CV8000 (Yokogawa) (15 images taken at 50 μm intervals). The 15 images were overlaid at minimum intensity to create a single composite image file (MinIP). The cyst area and number were quantified using the analysis support software provided with the CV6000, and the sum of the cyst areas was calculated.
[0158] 2. Results The inhibitory effects of PC1, CTF, CTT, and PC1(Arg1672fs97X) on cyst formation were evaluated using the empty pEBMulti-Hygb vector as a control. Cyst formation was suppressed by PC1 and CTF, but not by CTT and PC1(Arg1672fs97X) (Figure 3).
[0159] To investigate the region required for cyst formation inhibition, the cyst formation-inhibitory effects of CTF, stalk-TM(11), TM(11), TM(11)-CTT, TLD, Igκ-TLD, CD16.7-CTT, and R-CTF were evaluated using the empty pEBMulti-Hygb vector as a control. Of the constructs tested, CTF, Igκ-TLD, and CD16.7-CTT had the inhibitory effect on cyst formation (Figure 4). Comparison of CTF and stalk-TM(11) indicated that the CTT region was required for cyst formation inhibition. Furthermore, comparison of CTF with TM(11)-CTT, as well as the results for Igκ-TLD and CD16.7-CTT, suggested that inhibition of cyst formation requires at least a portion of the stalk or a signal sequence that localizes the CTT region to the cell membrane.
[0160] Example 2 To investigate whether membrane-translocating truncated PC1 polypeptides other than CD16.7-CTT and Igκ-TLD exhibit an inhibitory effect on cyst formation, an expression vector for a fusion protein of FAS and the CTT domain (FAS-CTT) (Table 3) was prepared in the same manner as in Example 1 using FAS, which is known to induce cell membrane localization (J. Exp. Med. Vol. 217 No. 12 e20291166 2020) (Figure 5), and the inhibitory effect on cyst formation was evaluated. As a result, FAS-CTT exhibited the same inhibitory effect on cyst formation as CD16.7-CTT (Figure 6).
[0161] Because membrane localization of the CTT region was thought to be necessary for the inhibition of cyst formation, a search was conducted for the CTT core region that is important for the inhibition of cyst formation. As in Example 1, expression vectors for the partial regions of the CTT region shown in Figure 7 (each consisting of a portion of the amino acid sequence from positions 4104 to 4303 of SEQ ID NO: 1) or fusion proteins of these regions with CD16.7 or FAS (Table 3) were constructed, and the inhibitory effect on cyst formation was evaluated. The results are shown in Figures 8-1 to 8-4.
[0162] With the exception of CTT-dNLS, no inhibitory effect on cyst formation was observed with only a partial region of the CTT region. On the other hand, fusion proteins of a partial region of the CTT region with CD16.7 or FAS showed an inhibitory effect on cyst formation. Of these, the inhibitory effect of CD16.7-CTT4104-4203 and CD16.7-CTT4254-4203 was weaker than that of other polypeptides. All polypeptides other than CD16.7-CTT4104-4203 and CD16.7-CTT4254-4303 had the amino acid sequence of positions 4204 to 4243 of SEQ ID NO: 1. From these results, it was inferred that the entire CTT region is not necessary for the inhibition of cyst formation, and that it is sufficient to include at least a portion of the CTT region, for example, at least a portion of positions 4154 to 4303 of SEQ ID NO: 1, particularly the partial region of the CTT region corresponding to positions 4204 to 4243.
[0163] Example 3 1. Test Method 1.1 Cellular Introduction of Expression Vector and Selection of Transfected Cells To confirm the intracellular localization of the truncated PC1 polypeptide, expression vectors for CTF, CTT, CD16.7-CTT, or FAS-CTT were transfected into MDCK cells in the same manner as in Example 1. 7 A suspension of 1 μg of expression vector in 10 μL of cell suspension at 100 cells / mL was set in a Neon Transfection System, and transformation by electroporation was performed under the conditions of voltage: 1150 V, width: 20 ms, number: 1, and the resulting solution was added to the medium (DMEM / F12 containing 10% FCS) (1 mL / well, 12-well plate). The next day, the medium was replaced with the above medium supplemented with 500 μg / mL hygromycin (Life Technologies Japan). After 5 days of culture, 2 × 10 cells were plated in a 12-well plate. 5 The cells were passaged to give 100 cells / well.
[0164] 1.2 Preparation of Cell Lysate: MDCK cells passaged onto a 12-well plate the day before were washed three times with PBS (cold) on ice (1 mL / well). After washing, 0.25 mg / mL EZ-link sNHS-SS-biotin (Thermofisher Scientific) solution was added to each well (400 μL / well) and the plate was left on ice for 30 minutes. The EZ-link sNHS-SS-biotin solution was then removed, and the plate was washed three times with DMEM (x1) (Gibco) (1 mL / well). After washing, 200 μL of 1×RIPA buffer (50 mM Tris-HCl pH 7.5 / 150 mM NaCl / 0.1% SDS / 0.5% SDC / 1% Triton X-100) containing 8 M urea was added to each well, and the cells were lysed by pipetting twice to obtain 400 μL of cell lysate. After thorough mixing, the protein concentration of the recovered solution was measured using EZQ. TM Protein quantitation was measured using a Protein Quantitation Kit (#R33200, Thermofisher Scientific). 2 μg of total protein from each sample was used for whole cell analysis, and the remaining sample was used for cell surface analysis.
[0165] 1.3 LC-MS Measurement 1.3.1 Preparation of Samples for LC-MS Analysis To prepare samples for cell surface analysis, each sample was mixed with an equal volume of 1×RIPA buffer containing 1 M arginine, and then the mixture was transferred to a Pierce tube. TMBiotinylated proteins were purified using Streptavidin Magnetic Beads (#88817, Thermofisher Scientific). Specifically, each sample was incubated with magnetically separated beads from 40 μL of bead solution for 1 hour at room temperature with stirring. Then, the beads were washed in 200 μL of wash buffer (1× RIPA buffer containing 8 M urea and 400 mM arginine) with stirring for 1 minute to allow the biotinylated sample to bind to the beads. The beads were then washed by stirring in 1 mL of wash buffer for 30 seconds, followed by magnetic separation and recovery, which was repeated three times. The washed beads were suspended in 50 mM DTT solution and incubated at room temperature for 1 hour, followed by magnetic separation and recovery of the supernatant, thereby separating the protein sample from biotin. The protein samples were then alkylated with 250 mM iodoacetamide (30 minutes of incubation with shaking at room temperature, protected from light). 2 μg of cell lysate (total protein) from the whole-cell analysis sample was reduced with 5 mM DTT (15 minutes of incubation at 70°C) and alkylated with 50 mM iodoacetamide (30 minutes of incubation with shaking at room temperature, protected from light). After reduction and alkylation, the cell surface analysis and whole-cell analysis samples were desalted and purified, followed by enzymatic digestion at 37°C for 18 hours using Trypsin / Lys-C Mix, Mass Spec Grade (#V5073, Promega, 0.025 μg per sample). The digested peptides were desalted and purified before analysis by LC-MS.
[0166] 1.3.2 LC-MS Analysis After trypsin digestion of the protein, the resulting peptides were analyzed by LC-MS. LC-MS was performed using an LC-MS system combining a nano-HPLC device (Ultimate 3000 nanoUHPLC, Thermofisher Scientific) with a mass spectrometer (Orbitrap Eclipse, Thermofisher Scientific) equipped with a gas-phase separation interface (FAIMS pro, Thermofisher Scientific). The nano-HPLC system used a column (stationary phase) consisting of a trap column (C18 Acclaim PepMap, Thermo Scientific) and a separation column (75 μm i.d., 12 cm long, 3 μm C18 particles, Nikkyo Technos) and gradient analysis was performed using reversed-phase chromatography with a 0.1% formic acid-acetonitrile mobile phase. The flow rate was 300 nl / min, and peptides were eluted with a linear gradient increasing the acetonitrile concentration from 4% to 35% over 48 minutes. Mass spectrometry was performed in positive ion mode using nanoelectrospray ionization. For cell surface analysis, full scan MS spectra were performed from m / z 375 to 1500, and product ion spectra were measured using data-dependent acquisition mode. Gas phase separation using FAIMS Pro was performed under three conditions: CV (compensation voltage) = -40 V, -60 V, and -80 V. Data obtained by LC-MS was analyzed using the analytical software Proteome Discoverer 3.0 (PD3.0, Thermofisher Scientific). Protein identification was performed using the SEQUEST search program included in PD3.0, searching against Uniprot's Dog Reference proteome (UP000002254), which contains expressed genes such as human PKD1 CTT. Quantitative analysis was performed using the label-free quantification method Precursor Ion Quantifier included in PD3.0.For whole-cell analysis, full-scan MS spectra were obtained from m / z 495 to 745, and product ion spectra were obtained using a data-independent acquisition mode with sequential isolation of precursor ions over a 4-Da band. Gas-phase separation using the FAIMS Pro was performed at CV = -45 V. MS raw data files were analyzed using the DIA-NN (Ver. 1.8.1) analysis software against the Uniprot Dog Reference proteome (UP000002254).
[0167] 2. Results The results of LC-MS analysis of truncated CTT polypeptide expression in MDCK cells are shown in Figures 9-1 and 9-2. Using whole-cell analysis samples, LC-MS analysis was performed using masses corresponding to two peptides within the CTT domain (Table 4, No. 1 and No. 2). Expression of all polypeptides, CD16.7-CTT, CTF, CTT, and FAS-CTT, was confirmed (Figure 9-1). On the other hand, when whole-cell analysis samples were used, LC-MS analysis was performed using masses corresponding to two peptides within the CTF 11-transmembrane domain (Table 4, No. 3 and No. 4). Expression of only CTF was confirmed (Figure 9-2). Expression of CD16.7-CTT, CTT, and FAS-CTT could not be confirmed because these polypeptides do not contain regions corresponding to the peptides shown in Figure 9-2.
[0168] The results of LC-MS analysis of the cell membrane localization of truncated CTT polypeptides in MDCK cells are shown in Figures 10-1 and 10-2. Using a cell surface analysis sample, LC-MS analysis was performed using masses corresponding to two types of peptides within the CTT domain (Table 4, No. 1 and No. 2). Expression of CD16.7-CTT and FAS-CTT was confirmed, but expression of CTF and CTT was not. Furthermore, LC-MS analysis was performed using a cell surface analysis sample with masses corresponding to two types of peptides within the CTF 11-transmembrane domain (Table 4, No. 5 and No. 4). CTF was detected, confirming its cell surface localization.
[0169] The results in Figures 9-1 to 9-2 and 10-1 to 10-2 indicate that the truncated polypeptides other than CTT (CD16.7-CTT, CTF, and FAS-CTT) are localized on the cell membrane.
[0170]
[0171]
Claims
1. A polynucleotide comprising a sequence encoding a truncated polycystin 1 (PC1) having an inhibitory effect on cyst formation, wherein the truncated PC1 comprises the C-terminal tail (CTT) region of PC1 or a part thereof.
2. The polynucleotide of claim 1, wherein the truncated PC1 is a membrane-localized polypeptide.
3. A polynucleotide comprising a sequence encoding truncated polycystin 1 (PC1), wherein the truncated PC1 is a membrane-localized polypeptide comprising the C-terminal tail (CTT) region of PC1 or a portion thereof.
4. A polynucleotide according to any one of claims 1 to 3, wherein the truncated PC1 comprises the CTT region of PC1.
5. A polynucleotide according to any one of claims 1 to 3, wherein the truncated PC1 comprises a portion of the CTT region of PC1.
6. A polynucleotide according to any one of claims 1 to 5, wherein the truncated PC1 further comprises at least a portion of the stalk of PC1.
7. The polynucleotide of claim 6, wherein the truncated PC1 further comprises at least one transmembrane region.
8. A polynucleotide according to any one of claims 1 to 5, wherein the truncated PC1 further comprises a signal sequence.
9. The polynucleotide of claim 8, wherein the truncated PC1 further comprises at least one transmembrane domain.
10. A truncated polycystin 1 (PC1) polypeptide encoded by the polynucleotide of any one of claims 1 to 9.
11. A vector comprising the polynucleotide according to any one of claims 1 to 9.
12. A pharmaceutical composition for treating a PKD1-associated disease, comprising the polynucleotide according to any one of claims 1 to 9, the polypeptide according to claim 10, or the vector according to claim 11.
13. A pharmaceutical composition for suppressing cyst formation in the kidney, comprising a polynucleotide containing a sequence encoding a truncated polycystin 1 (PC1) containing the C-terminal tail (CTT) region or a portion thereof, or a vector containing said polynucleotide, and suppressing cyst formation by localizing the CTT region or a portion thereof to the cell membrane.
